Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Bioequivalence study
Status
Ended
Participants planned
36
Countries
1
Sites
1
Healthy
Key facts
- Sponsor
- Farmak JSC
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 10 Aug 2024 → 27 Sep 2024
- Decision date (initial)
- 2024-05-06
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Healthy
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Farmak JSC
- Sponsor organisation
- Farmak JSC
- Address
- Vul. Kyrylivska 63
- City
- M. Kyiv
- Postcode
- 04080
- Country
- Ukraine
Scientific contact point
- Organisation
- Farmak JSC
- Contact name
- Olena Barbukho
Public contact point
- Organisation
- Farmak JSC
- Contact name
- Olena Barbukho
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Poland | Ended | 36 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Poland | 2024-08-10 | 2024-09-27 | 2024-08-10 | 2024-08-29 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-01-08 | Poland | Acceptable 2024-04-29
|
2024-05-06 |